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Table 3. Risk factor for clinical failure via endoscopic treatment of MBO in patients 







Univariate analysis  Multivariate analysis 
  n=14 n=31 OR 95% CI p-value   OR 95% CI p-value 
Age, (>67 years), n (%) 7 (50.0%) 16 (51.6%) 0.9 0.3-3.3 0.92     
Sex, male, n (%) 8 (57.1%) 21 (67.7%) 0.6 0.2-2.3 0.49     
Etiology of MBO, n (%)          
   Malignant biliary disease 4(28.6%) 12(38.7%) 0.6 0.1-2.4 0.51     
   Malignant pancreatic disease 3(21.4%) 10(32.3%) 0.6 0.1-2.3 0.45     
   Gastric cancer 6(42.9%) 6(19.4%) 3.1 0.8-12.9 0.11      
   Colon cancer 0(0%) 3(9.7%) 0  0.13     
   Hepatocellular carcinoma 1(7.1%) 0(0%) -  0.13     
Type of MBO, n (%)   0.9 0.2-7.0 0.90      
    Primary disease 2(14.3%) 4(12.9%)        
    Recurrent disease 12(85.7%) 27(87.1%)        
       Liver metastasis 2(14.3%) 10(32.3%)        
       Lymph node metastasis 3(21.4%) 4(12.9%)        
       Local recurrence 7(50.0%) 13(41.9%)        
Location of MBO, n (%)   2.2 0.6-8.3 0.26     
    Hilar or HJ anastomosis 8(57.1%) 23(74.2%)        
    Distal 6(42.9%) 8(25.8%)        
Presence of peritoneal dissemination, n (%) 8 (57.1%) 5 (16.1%) 6.9 1.7-31.3 0.006  6.8 1.6-32.8 0.008 
Digestive reconstruction, n (%)          
    Modified Child’s method 3(21.4%) 15(48.4%) 0.3 0.1-1.1 0.08  0.3 0.1-1.3 0.12 
    RY gastorejejunostomy 5(35.7%) 8(25.8%) 1.6 0.4-6.2 0.50      
    RY hepaticojejunostomy 4(28.6%) 5(16.1%) 2.1 0.4-9.5 0.34      
    Billroth II with gastrectomy 2(14.3%) 3(9.7%) 1.6 0.2-10.6 0.66     
Presence of native papilla, n (%) 7 (50.0%) 11 (35.5%) 1.8 0.5-6.7 0.36     
Time from surgery to ERCP (>505 days), n (%) 5 (35.7%) 18 (58.1%) 0.4 0.1-1.4 0.16     
T-Bil (>2.5 mg/dL), n (%) 9 (64.3%) 13 (41.9%) 2.5 0.7-9.8 0.16      
AST (>80 IU/L), n (%) 8 (57.1%) 14 (45.2%) 1.6 0.5-6.0 0.46      
ALT (>72 IU/L), n (%) 8 (57.1%) 14 (45.2%) 1.6 0.5-6.0 0.46      
γGTP (>364 IU/L), n (%) 8 (57.1%) 13 (41.9%) 1.8 0.5-6.9 0.34      
ALP (>1205 IU/L), n (%) 6 (42.9%) 15 (48.4%) 0.8 0.2-2.8 0.73      
Type of scope, n (%)   1.5 0.4-7.8 0.59      
     EI-580BT 3(21.4%) 9(29.0%)        
     Other scope 11(78.6%) 22(71.0%)               
 
MBO, malignant biliary obstruction; HJ, hepaticojejunostomy; RY, Roux-en-Y; ERCP, 
endoscopic retrograde cholangiopancreatography; TB, total bilirubin; AST, aspartate 
aminotransaminase; ALT, alanine aminotransferase; γGTP, g-glutamyl 
transpeptidase; ALP, alkaline phosphatase; OR, odds ratio; CI, confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
